Kitov Pharma Ltd (NASDAQ:KTOV) and Emergent BioSolutions Inc. (NYSE:EBS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kitov Pharma Ltd||1.00M||22.21||5.20M||-0.37||0.00|
|Emergent BioSolutions Inc.||782.40M||3.45||62.70M||1.14||50.80|
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Kitov Pharma Ltd and Emergent BioSolutions Inc.
Table 2 provides us Kitov Pharma Ltd and Emergent BioSolutions Inc.’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Kitov Pharma Ltd||-520.00%||0%||0%|
|Emergent BioSolutions Inc.||8.01%||6.6%||4.5%|
The table delivered features the ratings and recommendations for Kitov Pharma Ltd and Emergent BioSolutions Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Kitov Pharma Ltd||0||0||0||0.00|
|Emergent BioSolutions Inc.||0||2||3||2.60|
Competitively Emergent BioSolutions Inc. has an average target price of $70.6, with potential upside of 33.74%.
Insider & Institutional Ownership
Kitov Pharma Ltd and Emergent BioSolutions Inc. has shares owned by institutional investors as follows: 20.28% and 85%. Insiders Competitively, owned 3.4% of Emergent BioSolutions Inc. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Kitov Pharma Ltd||0%||-16.54%||-11.45%||-43.62%||-56.56%||60.61%|
|Emergent BioSolutions Inc.||-5.49%||-7.58%||-20.29%||-7.79%||17.08%||-2.73%|
For the past year Kitov Pharma Ltd has 60.61% stronger performance while Emergent BioSolutions Inc. has -2.73% weaker performance.
On 10 of the 12 factors Emergent BioSolutions Inc. beats Kitov Pharma Ltd.
Kitov Pharmaceuticals Holdings Ltd., through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The companyÂ’s lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. Kitov Pharmaceuticals Holdings Ltd. was founded in 2010 and is headquartered in Tel Aviv, Israel.
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.